- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Venetoclax
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–262
of 262
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Zinc, Placebos for zinc and nicotinamide riboside, Nicotinamide riboside
- Drug · Other
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- BI 1015550, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 45 more
- Conditions
- Pulmonary Fibrosis
- Interventions
- BMS-986278
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Ocala, Florida • Philadelphia, Pennsylvania
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Tralokinumab, Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 50 Years to 79 Years
- Enrollment
- 409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • La Jolla, California • Sacramento, California + 18 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- bosentan, Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 13 more
- Conditions
- Constipation Chronic Idiopathic, Cystic Fibrosis
- Interventions
- Maralixibat 9.5 MG/ML [Livmarli]
- Drug
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Nintedanib, Pirfenidone
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 6
- States / cities
- Danbury, Connecticut • New Orleans, Louisiana • Minneapolis, Minnesota + 3 more
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- MNKD-201(Nintedanib DPI), Placebo
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 9
- States / cities
- Fresno, California • Palm Springs, California • Doral, Florida + 5 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- BBT-877, Single dose, Placebo group, BBT-877, Multiple doses
- Drug
- Lead sponsor
- Bridge Biotherapeutics, Inc.
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- PRM-151 (Zinpentraxin Alfa)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- Not listed
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Sacramento, California • San Diego, California + 37 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- EGCG 300 mg, Placebo for EGCG 300 mg, EGCG 600 mg, Placebo for EGCG 600 mg
- Drug
- Lead sponsor
- Hal Chapman
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • Charlottesville, Virginia
- Conditions
- Idiopathic Pulmonary Fibrosis, Depression, Anxiety, Depressive Disorder, Anxiety Disorders, Anxiety Depression
- Interventions
- Palliative Care, Standard of Care
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Idiopathic Pulmonary Fibrosis, Lung Transplant; Complications
- Interventions
- Nintedanib, Placebo Oral Tablet
- Drug
- Lead sponsor
- Temple University
- Other
- Eligibility
- 35 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- BI 765423, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Gainesville, Florida • Ocala, Florida + 11 more
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Buloxibutid, Placebo
- Drug
- Lead sponsor
- Vicore Pharma AB
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Redding, California • Sacramento, California + 19 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- CAL101, Placebo
- Drug
- Lead sponsor
- Calluna Pharma AS
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Denver, Colorado • Miami, Florida + 6 more
- Conditions
- Pulmonary Fibrosis
- Interventions
- Not listed
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2035
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Blood draw, Questionnaire
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
- Interventions
- Treprostinil sodium for inhalation
- Drug
- Lead sponsor
- Lung Biotechnology PBC
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 6
- States / cities
- La Jolla, California • Sacramento, California • Ann Arbor, Michigan + 3 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- NAL ER, Placebo
- Drug
- Lead sponsor
- Trevi Therapeutics
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 16
- States / cities
- Tuscaloosa, Alabama • New Britain, Connecticut • Wilmington, Delaware + 12 more
- Conditions
- Interstitial Lung Disease, Pulmonary Fibrosis
- Interventions
- [68Ga]CBP8, Gadoterate Meglumine
- Drug
- Lead sponsor
- Peter Caravan
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts